In a report in the Journal of Clinical Oncology, Francois-Xavier Mahon, MD, PhD, and colleagues provided the final analysis of the European Stop Kinase Inhibitors (EURO-SKI)...
In an analysis of two trials (SCOT and IDEA-HORG) reported in the Journal of Clinical Oncology, Domingo et al identified the predictive value of Immunoscore for disease-free...
The composition of the gut microbiome may reveal distinct signatures associated with race, ethnicity, and age of onset in patients with colorectal cancer...
On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed...
In an analysis of 9-year outcomes of a Chinese trial (ESECC) reported in the Journal of Clinical Oncology, Liu et al found that endoscopic screening for esophageal...
Doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations recently issued a joint statement urging the nation’s health-care systems, physicians, parents, children, and young adults to get human papillomavirus (HPV) vaccination back on ...
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
In a new study designed to provide a more comprehensive picture of how a diverse cohort of patients with gynecologic cancer are affected by financial distress, nearly half reported financial toxicity, which was associated with economic cost-coping strategies. These findings were reported by Esselen ...
In a retrospective cohort study reported in JAMA Oncology, Erickson et al found that real-world use of targeted therapy after diagnosis of intracranial metastatic disease was associated with improved overall survival vs no use of targeted therapy in patients with HER2-positive breast cancer,...
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
As reported in The Lancet Oncology by Justin F. Gainor, MD, and colleagues, an interim analysis of the phase I/II ARROW trial has shown that the oral RET inhibitor pralsetinib produced high response rates in previously treated and treatment-naive patients with advanced RET fusion–positive non–small ...
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...